Acer Therapeutics Reports Positive Results From Pivotal Clinical Trial of EDSIVO™ (celiprolol) for Treatment of Vascular Ehlers-Danlos Syndrome | oneedsvoice

welcome to oneEDSvoice

- a positively charged Ehlers Danlos Syndrome community.
  • join today!

Acer Therapeutics Reports Positive Results From Pivotal Clinical Trial of EDSIVO™ (celiprolol) for Treatment of Vascular Ehlers-Danlos Syndrome


Acer Therapeutics Inc., (Nasdaq:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced positive results from the pivotal clinical trial of EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS).

https://media.oneedsvoice.com/wp-content/uploads/2017/07/acer-1.png

expertly curated content related to this topic